Zacharon Pharmaceuticals, a San Diego startup that got $3.5 million in venture capital and a $2.2 million research grant in 2008, has raised another $500,000 in additional funding that includes debt, securities, and warrants or rights, according to a recent regulatory filing. The company intends to raise $1.9 million. As Luke reported two years ago, Zacharon is developing small molecule drugs to block the production of complex carbohydrates known as glycans, which can alter the function of proteins. While investors were not disclosed, Zacharon’s initial funding came from San Diego’s Avalon Ventures and Avalon partner Jay Lichter remains on the board. Although Lichter served as CEO two years ago, Robin Jackman is now identified as the biotech’s president and CEO.